NewCardio Receives European Patent For CardioBip(TM)

Main Category: Cardiovascular / Cardiology
Article Date: 06 Mar 2008 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

NewCardio, Inc. (OTCBB: NWCI), a development-stage cardiac diagnostic and services company, announced that it has received a Certificate of Grant from the European Patent Office covering CardioBip™, its proprietary device and methodology for transtelephonic transmission of comprehensive ECG data.

The patent award adds to the company's robust IP portfolio, which includes U.S. Patents, awarded on September 4, 2007, for technology underlying its VisualECG™ and QTinno™ products, and several U.S. and international patent applications currently under review.

The CardioBip is a unique, hand-held device that provides a solution to the problem of urgent ECG telemonitoring. The CardioBip is capable of providing truly comprehensive and accurate ECG data that is being transmitted wirelessly. What makes CardioBip unique is the extreme ease of use, combined with the ability to generate a standard 12 lead ECG recording. The CardioBip works without any cables and the device's electrodes are integrated, offering a potential for integration with popular hand-held PDA platforms.

The patent application was submitted under the Patent Cooperation Treaty (PCT) with 33 claims covering the device, related systems and methods of use. All 33 claims were allowed by the European Patent Office on its first office action. The same application is currently being reviewed in the U.S., China, Japan, and Korea, and the Company is awaiting first office actions from these countries.

Branislav Vajdic, Ph.D., chief executive officer of NewCardio, Inc., commented, "We believe the CardioBip technology has an important role to play in detection and monitoring of potentially fatal cardiac diseases. Thus, we are gratified by the European Patent Office's broad grant of patent rights. We look forward to hearing soon from other patent offices, including the U.S. Patent and Trademark Office. NewCardio is committed to advancing the widely accepted 12-lead ECG to deliver innovation to the cardiac sciences."

About NewCardio, Inc.

NewCardio is a development-stage cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide dramatically higher accuracy to, and thus significantly increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. The company's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio intends to initially compete in two large segments of the CVD diagnostic market: cardiac safety in drug development and diagnostics. For more information, visit http://www.newcardio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than those that are purely historical are forward-looking statements. Words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions also identify forward-looking statements. Forward-looking statements include, without limitation, statements regarding the development of the company's proprietary technology platform and its products, the timing of such development and the timing and results of clinical trials and regulatory review. All statements in this press release other than those that are purely historical are forward-looking statements. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties.

There are important factors that could cause the company's actual results to differ materially from those in the forward-looking statements. These factors, include, without limitation, the following: the company's ability to develop its technology platform and its products; the company's ability to protect its intellectual property; the risk that the company will not be able to develop the technology platform and products in the current projected timeframe; the risk that the products will not achieve performance standards in clinical trials; the risk that the clinical trial process will take longer than projected; the risk that the products will not receive regulatory approval; the risk that the regulatory review process will take longer than projected; the company's ability to commercialize its products; any of which could impact sales, costs and expenses and/or planned strategies. Additional information regarding factors that could cause results to differ can be found in the company's most recent filings with the U.S. Securities and Exchange Commission (the "SEC"), including, without limitation, its current report on Form 8-K/A filed with the SEC on January 22, 2008.

These forward-looking statements are based on information as of March 4, 2008, and the company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized.

NewCardio, Inc.